PCSK9 is the ninth member of the PC family programmed ... including tumorigenic signaling pathways, the tumor microenvironment (TME), and ferroptosis (Figure 2). Among them, cholesterol exerts ...

PCSK9 and APOA4 were identified as key regulatory genes in the cholesterol metabolic pathway. PCSK9 knockdown increased APOA4 expression, while APOA4 overexpression led to reduced PCSK9 expression.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that binds to the LDL receptor on hepatocytes, promoting its internalization and degradation within the cell. [Repatha package ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

"We've had PCSK9 inhibitors on the market in the United States for 10 years," said investigator Michael Koren, MD, a cardiologist and CEO of the ENCORE Research Group in Jacksonville, Florida.

Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort ...

However, the impact of the PCSK9 inhibitors will be much greater ... Moreover, as a biologic agent, there will not be a simple pathway to cheaper generics in a 10-15 year timeframe, points out ...

A once-daily oral PCSK9 inhibitor reduced LDL in patients with hypercholesterolemia. Safety and tolerability profiles were favorable, according to investigators. CHICAGO — In a phase 2b study ...

Verve Therapeutics reported that a single infusion of VERVE-102 resulted in dose-dependent reductions in blood PCSK9 protein levels and LDL-C in the Heart-2 study, with an average LDL-C decrease ...